ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 58 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,574 | -64.3% | 18,783 | 0.0% | 0.00% | -62.5% |
| Q1 2024 | $18,407 | +47.6% | 18,783 | 0.0% | 0.01% | +100.0% |
| Q4 2023 | $12,472 | -11.1% | 18,783 | 0.0% | 0.00% | -20.0% |
| Q3 2023 | $14,031 | -23.1% | 18,783 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $18,238 | +11.1% | 18,783 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $16,416 | -8.3% | 18,783 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $17,900 | -14.8% | 18,783 | 0.0% | 0.01% | -14.3% |
| Q3 2022 | $21,000 | -8.7% | 18,783 | 0.0% | 0.01% | -12.5% |
| Q2 2022 | $23,000 | -42.5% | 18,783 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $40,000 | -82.1% | 18,783 | 0.0% | 0.01% | -72.4% |
| Q4 2021 | $223,000 | -23.4% | 18,783 | 0.0% | 0.03% | +7.4% |
| Q3 2021 | $291,000 | -24.0% | 18,783 | 0.0% | 0.03% | -27.0% |
| Q2 2021 | $383,000 | – | 18,783 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,457,937 | $510,278 | 0.66% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $260,125 | 0.20% |
| Vivo Capital, LLC | 3,547,030 | $1,241,461 | 0.12% |
| Opaleye Management Inc. | 1,260,000 | $441,000 | 0.10% |
| EcoR1 Capital, LLC | 6,389,468 | $2,236,314 | 0.07% |
| Deep Track Capital, LP | 6,102,770 | $2,135,970 | 0.06% |
| TANG CAPITAL MANAGEMENT LLC | 1,650,000 | $577,500 | 0.06% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 655,515 | $229,430 | 0.05% |
| Newtyn Management, LLC | 719,287 | $251,750 | 0.05% |
| ARMISTICE CAPITAL, LLC | 7,256,410 | $2,539,744 | 0.03% |